Lonsurf 20 mg/8.19 mg film-coated tablets clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
This study compares a new medicine, Telisotuzumab Adizutecan, with a standard treatment (Lonsurf plus Bevacizumab) for advanced bowel cancer that has spread. It focuses on patients whose cancer has a specific protein called c-Met. The aim is to find out which treatment is safer and more effective.
For: Metastatic Colorectal CancerGermany · Poland · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixeddose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
This study is testing a new combination medicine (relatlimab-nivolumab) for advanced bowel cancer that has spread. It compares it to existing treatments (Lonsurf or Stivarga) to see if it helps people live longer and improves their quality of life.
For: Metastatic Colorectal CancerBelgium · Spain · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Openlabel, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
This study looks at new treatments for bowel cancer that has spread and has a specific gene change (KRAS p.G12C mutation). It compares a new drug combination (sotorasib and panitumumab) with standard treatments to see which works best and is safest.
For: Colorectal Cancer (CRC)Italy · Germany · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy (BOOG 2019-01 TIBET study)
This study looks at a new treatment called Lonsurf for women with advanced breast cancer that's grown despite other treatments. We want to see how many patients' cancer stops growing or shrinks after 8 weeks on Lonsurf.
For: Advanced breast cancerNetherlands